Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Drug or technology

AL8326

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

SEP 10, 2026 · PHASE 1/2 TRIAL

A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers

ClinicalTrials.gov

This is a Phase 1b/2a trial registry record with no results posted; it describes a planned study design and enrollment strategy only.

PreliminaryNCT07811232 Advenchen Pharmaceuticals AL8326

Reported

Planned enrollment138

Study phasePhase 1b/2a

Primary outcome measure 1Recommended Combination Dose (RCD) at 36 mo…

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support